RESUMEN
After Alzheimer's disease, Parkinson's disease (PD) has taken second place in becoming one of the most commonly occurring neurological diseases being responsible for a number of disabling motor symptoms ranging from bradykinesia, akinesia, tremors to rigidity, that mostly targets the elderly population and severely disrupts their quality of life. The true underlying pathology of PD yet remains a mystery, however, recent advances in the field have pointed towards the production of α-synuclein aggregates, oxidative stress, and an imbalance between levels of acetylcholine and dopamine neurotransmitters in the brain that have been shown to result in loss of coordinated movement. Current treatments of PD include the gold standard dopamine precursor L-dopa, dopamine agonists pergolide and bromocriptine, catechol-o-methyl transferases inhibitors, entacapone and tolcapone and monoamine oxidase inhibitors such as Selegine and Rasagiline amongst several other drugs. While these drugs are successful in treating motor symptoms of the disease, they do so with a plethora of side effects that are especially debilitating to the elderly. In the recent years, a considerable amount of attention has been shifted towards phytocompounds such as flavonoids and green tea catechins due to promising experimental results. In this review, we have compiled phytocompounds that have shown potent activity against some of the most important targets for antiparkinsonian therapy. These compounds have exhibited activities that transcend the limits of simply attenuating mitochondrial oxidative stress and have opened doors to the discovery of novel lead compounds for newer, efficacious antiparkinsonian therapies with wider therapeutic windows.
Asunto(s)
Antiparkinsonianos/uso terapéutico , Productos Biológicos/uso terapéutico , Agonistas de Dopamina/uso terapéutico , Enfermedad de Parkinson/tratamiento farmacológico , Extractos Vegetales/uso terapéutico , Animales , Antiparkinsonianos/aislamiento & purificación , Antiparkinsonianos/farmacología , Productos Biológicos/aislamiento & purificación , Productos Biológicos/farmacología , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Encéfalo/patología , Agonistas de Dopamina/aislamiento & purificación , Agonistas de Dopamina/farmacología , Humanos , Levodopa/farmacología , Levodopa/uso terapéutico , Inhibidores de la Monoaminooxidasa/farmacología , Inhibidores de la Monoaminooxidasa/uso terapéutico , Enfermedad de Parkinson/metabolismo , Enfermedad de Parkinson/patología , Extractos Vegetales/aislamiento & purificación , Extractos Vegetales/farmacocinéticaRESUMEN
Despite intense interest in expanding chemical space, libraries containing hundreds-of-millions to billions of diverse molecules have remained inaccessible. Here we investigate structure-based docking of 170 million make-on-demand compounds from 130 well-characterized reactions. The resulting library is diverse, representing over 10.7 million scaffolds that are otherwise unavailable. For each compound in the library, docking against AmpC ß-lactamase (AmpC) and the D4 dopamine receptor were simulated. From the top-ranking molecules, 44 and 549 compounds were synthesized and tested for interactions with AmpC and the D4 dopamine receptor, respectively. We found a phenolate inhibitor of AmpC, which revealed a group of inhibitors without known precedent. This molecule was optimized to 77 nM, which places it among the most potent non-covalent AmpC inhibitors known. Crystal structures of this and other AmpC inhibitors confirmed the docking predictions. Against the D4 dopamine receptor, hit rates fell almost monotonically with docking score, and a hit-rate versus score curve predicted that the library contained 453,000 ligands for the D4 dopamine receptor. Of 81 new chemotypes discovered, 30 showed submicromolar activity, including a 180-pM subtype-selective agonist of the D4 dopamine receptor.
Asunto(s)
Agonistas de Dopamina/química , Agonistas de Dopamina/aislamiento & purificación , Simulación del Acoplamiento Molecular/métodos , Bibliotecas de Moléculas Pequeñas/química , Bibliotecas de Moléculas Pequeñas/aislamiento & purificación , Inhibidores de beta-Lactamasas/química , Inhibidores de beta-Lactamasas/aislamiento & purificación , Proteínas Bacterianas/antagonistas & inhibidores , Proteínas Bacterianas/química , Cristalografía por Rayos X , Humanos , Ligandos , Aprendizaje Automático , Observación , Receptores de Dopamina D4/agonistas , Receptores de Dopamina D4/química , Receptores de Dopamina D4/metabolismo , beta-Lactamasas/químicaRESUMEN
Ergotism is the long-term ergot poisoning by ingestion of rye or other grains infected with the fungus Claviceps purpurea and more recently by excessive intake of ergot drugs. It has either neuropsychiatric or vascular manifestations. In the Middle Ages, the gangrenous poisoning was known as St. Anthony's fire, after the order of the Monks of St. Anthony who were particularly skilled at treating the condition. In 1917, Prof. Arthur Stoll returned home to Switzerland from Germany, to lead the development of a new pharmaceutical department at Sandoz Chemical Company. Stoll, using the special methods of extraction learned from his work with his mentor Willstetter, started his industrial research work with ergot. He succeeded in isolating, from the ergot of rye, ergotamine as an active principle of an old popular remedy for excessive post-partum bleeding. The success of this discovery occurred in 1918 and was translated into a pharmaceutical product in 1921 under the trade name Gynergen. In subsequent work, Stoll and his team were leaders in identifying the structure of the many other alkaloids and amines produced by Claviceps purpurea This was the cultural background and scientific foundation on which bromocriptine was discovered.
Asunto(s)
Antiparkinsonianos/uso terapéutico , Bromocriptina/uso terapéutico , Agonistas de Dopamina/uso terapéutico , Descubrimiento de Drogas/historia , Enfermedad de Parkinson/tratamiento farmacológico , Acromegalia/tratamiento farmacológico , Acromegalia/historia , Animales , Aniversarios y Eventos Especiales , Antiparkinsonianos/historia , Antiparkinsonianos/aislamiento & purificación , Antiparkinsonianos/envenenamiento , Bromocriptina/aislamiento & purificación , Bromocriptina/metabolismo , Bromocriptina/envenenamiento , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/historia , Agonistas de Dopamina/historia , Agonistas de Dopamina/aislamiento & purificación , Agonistas de Dopamina/envenenamiento , Quimioterapia Combinada/efectos adversos , Quimioterapia Combinada/historia , Ergotismo/etiología , Ergotismo/historia , Historia del Siglo XX , Antagonistas de Hormonas/efectos adversos , Antagonistas de Hormonas/historia , Antagonistas de Hormonas/uso terapéutico , Humanos , Hiperprolactinemia/tratamiento farmacológico , Hiperprolactinemia/historia , Hipoglucemiantes/efectos adversos , Hipoglucemiantes/historia , Hipoglucemiantes/uso terapéutico , Enfermedad de Parkinson/historia , Neoplasias Hipofisarias/tratamiento farmacológico , Neoplasias Hipofisarias/historiaRESUMEN
Fatigue is a common and serious health problem, and various dietary interventions have previously been employed to ameliorate fatigue. The aim of the current study was to investigate the antifatigue effects of Danish porcine placenta (DPP) and its major dipeptides, including leucineglycine (LG) and glycineleucine (GL). The antifatigue effects of orally administered DPP, LG and GL were determined using a treadmill exercise test and a forced swimming test (FST) in mice. Additionally, the antiinflammatory effects of DPP, LG and GL were investigated in activated splenocytes. The results demonstrated that oral treatment of mice with DPP, LG and GL increased the time to exhaustion during treadmill exercise. Furthermore, DPP, LG and GL enhanced the levels of dopamine, brainderived neurotrophic factor and phosphorylated-extracellular signalregulated kinase in the brains of mice with treadmill exerciseinduced exhaustive fatigue, and decreased levels of certain proinflammatory cytokines in the serum and spleen, as determined by ELISA and western blot analysis. Following treadmill exercise, commercial kits were employed to demonstrate that DPP, LG and GL reduced the levels of lactate dehydrogenase, lactate, creatine kinase, blood urea nitrogen, alanine transaminase and aspartate transaminase in the muscle and/or serum of mice. In addition, DPP, LG and GL enhanced the muscle and liver glycogen levels, catalase activity in the liver and serum superoxide dismutase activity. DPP, LG and GL also increased the proliferation of splenocytes and inhibited proinflammatory cytokine production by reducing the activation of caspase1 and nuclear factorκB in activated splenocytes, as determined by MTT assays, ELISA and western blotting, respectively. Furthermore, DPP, LG and GL reduced immobility time in the FST in mice. In conclusion, DPP may limit intensive exerciseinduced fatigue by increasing dopaminergic systems and inhibiting inflammatory responses.
Asunto(s)
Estimulantes del Sistema Nervioso Central/farmacología , Dipéptidos/farmacología , Agonistas de Dopamina/farmacología , Dopamina/metabolismo , Neuronas Dopaminérgicas/efectos de los fármacos , Fatiga/prevención & control , Animales , Factor Neurotrófico Derivado del Encéfalo/genética , Factor Neurotrófico Derivado del Encéfalo/metabolismo , Caspasa 1/genética , Caspasa 1/metabolismo , Estimulantes del Sistema Nervioso Central/aislamiento & purificación , Dipéptidos/aislamiento & purificación , Agonistas de Dopamina/aislamiento & purificación , Neuronas Dopaminérgicas/metabolismo , Prueba de Esfuerzo , Fatiga/genética , Fatiga/metabolismo , Fatiga/fisiopatología , Femenino , Regulación de la Expresión Génica , Masculino , Ratones , Proteína Quinasa 1 Activada por Mitógenos/genética , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , Proteína Quinasa 3 Activada por Mitógenos/genética , Proteína Quinasa 3 Activada por Mitógenos/metabolismo , FN-kappa B/genética , FN-kappa B/metabolismo , Condicionamiento Físico Animal/métodos , Esfuerzo Físico/efectos de los fármacos , Placenta/química , Embarazo , PorcinosRESUMEN
Dopamine receptors are implicated in the pathogenesis and treatment of nearly every neuropsychiatric disorder. Although thousands of drugs interact with these receptors, our molecular understanding of dopaminergic drug selectivity and design remains clouded. To illuminate dopamine receptor structure, function, and ligand recognition, we determined crystal structures of the D4 dopamine receptor in its inactive state bound to the antipsychotic drug nemonapride, with resolutions up to 1.95 angstroms. These structures suggest a mechanism for the control of constitutive signaling, and their unusually high resolution enabled a structure-based campaign for new agonists of the D4 dopamine receptor. The ability to efficiently exploit structure for specific probe discovery-rapidly moving from elucidating receptor structure to discovering previously unrecognized, selective agonists-testifies to the power of structure-based approaches.
Asunto(s)
Agonistas de Dopamina/química , Receptores de Dopamina D4/química , Sitio Alostérico , Antipsicóticos/química , Benzamidas/química , Agonistas de Dopamina/aislamiento & purificación , Humanos , Conformación Proteica , Receptores de Dopamina D4/ultraestructura , Relación Estructura-ActividadRESUMEN
AIM: Development of a high-sensitivity chiral LC-MS/MS method was required to evaluate a combination of pramipexole (S-PPX) and its enantiomer dexpramipexole (R-PPX) in a proposed clinical trial. The previously available methods suffered from low sensitivity for the (S)-enantiomer in the presence of the more abundant (R)-enantiomer. Based on the projected dosing regimen in the clinical trial, a 5000-fold improvement in sensitivity was required for the (S)-enantiomer. METHODOLOGY: Spiked human plasma samples were extracted by liquid-liquid extraction using ethyl acetate and injected onto a CHIRALPAK ID column under pH gradient conditions. CONCLUSION: An improved analytical method was developed and validated with a final LLQ for (S)-PPX of 0.1 ng/ml in the presence of 2000 ng/ml of (R)-PPX.
Asunto(s)
Antiparkinsonianos/sangre , Benzotiazoles/sangre , Agonistas de Dopamina/sangre , Extracción Líquido-Líquido/métodos , Espectrometría de Masas en Tándem/métodos , Antiparkinsonianos/aislamiento & purificación , Benzotiazoles/aislamiento & purificación , Cromatografía Líquida de Alta Presión/métodos , Agonistas de Dopamina/aislamiento & purificación , Humanos , Límite de Detección , Pramipexol , Reproducibilidad de los ResultadosRESUMEN
The griseorhodins belong to a family of extensively modified aromatic polyketides that exhibit activities such as inhibition of HIV reverse transcriptase and human telomerase. The vast structural diversity of this group of polyketides is largely introduced by enzymatic oxidations, which can significantly influence the bioactivity profile. Four new compounds, griseorhodins D-F, were isolated from a griseorhodin producer, Streptomyces sp. CN48+, based upon their enhancement of calcium uptake in a mouse dorsal root ganglion primary cell culture assay. Two of these compounds, griseorhodins D1 and D2, were shown to be identical to the major, previously uncharacterized products of a grhM mutant in an earlier griseorhodin biosynthesis study. Their structures enabled the establishment of a more complete hypothesis for the biosynthesis of griseorhodins and related compounds. The other two compounds, griseorhodins E and F, represent new products of post-polyketide synthase tailoring in griseorhodin biosynthesis and showed significant binding activity in a human dopamine active transporter assay.
Asunto(s)
Naftoquinonas/aislamiento & purificación , Naftoquinonas/farmacología , Policétidos/aislamiento & purificación , Policétidos/farmacología , Streptomyces/química , Animales , Agonistas de Dopamina/química , Agonistas de Dopamina/aislamiento & purificación , Humanos , Ratones , Estructura Molecular , Complejos Multienzimáticos/metabolismo , Familia de Multigenes , Naftoquinonas/química , Resonancia Magnética Nuclear Biomolecular , Filipinas , Sintasas Poliquetidas/metabolismo , Policétidos/química , Streptomyces/genética , Telomerasa/antagonistas & inhibidoresRESUMEN
Implantation of a retrogradely shed endometrium during menstruation requires an adequate blood supply, which allows the growth of endometriotic lesions. This suggests that the development of endometriosis can be impaired by inhibiting angiogenesis. The growth of endometriotic foci is impaired by commercial oncological antiangiogenic drugs used to block vascular endothelial growth factor (VEGF) signaling. The dopamine agonist cabergoline (Cb2) inhibits the growth of established endometriosis lesions by exerting antiangiogenic effects through VEGFR2 inactivation. However, the use of ergot-derived Cb2 is associated with an increased incidence of cardiac valve regurgitation. To evaluate the potential usage of non-ergot-derived dopamine agonists for the treatment of human endometriosis, we compared the efficacy of quinagolide with that of Cb2 in preventing angiogenesis and vascularization in a heterologous mouse model of endometriosis. Nude mice whose peritoneum had been implanted with eutopic human endometrial fragments were treated with vehicle, 50â µg/kg per day oral Cb2, or 50 or 200â µg/kg per day quinagolide during a 14-day period. At the end of the treatment period, the implants were excised in order to assess lesion size, cell proliferation, degree of vascularization, and angiogenic gene expression. Neoangiogenesis was inhibited and the size of active endometriotic lesions, cellular proliferation index, and angiogenic gene expression were significantly reduced by both dopamine agonists when compared with the placebo. Given that Cb2 and quinagolide were equally effective in inhibiting angiogenesis and reducing lesion size, these experiments provide the rationale for pilot studies to explore the use of non-ergot-derived dopamine agonists for the treatment of endometriosis in humans.
Asunto(s)
Modelos Animales de Enfermedad , Agonistas de Dopamina/farmacología , Endometriosis/patología , Ergolinas/farmacología , Ratones , Enfermedades Uterinas/patología , Animales , Vasos Sanguíneos/efectos de los fármacos , Vasos Sanguíneos/patología , Cabergolina , Recuento de Células , Proliferación Celular/efectos de los fármacos , Claviceps/química , Agonistas de Dopamina/aislamiento & purificación , Endometriosis/metabolismo , Endometrio/irrigación sanguínea , Endometrio/efectos de los fármacos , Endometrio/metabolismo , Endometrio/patología , Ergolinas/aislamiento & purificación , Femenino , Humanos , Neovascularización Patológica/metabolismo , Neovascularización Patológica/patología , Receptores de Dopamina D2/metabolismo , Enfermedades Uterinas/metabolismo , Receptor 2 de Factores de Crecimiento Endotelial Vascular/metabolismoRESUMEN
D5 receptor is a subtype of dopamine D1-like receptor, and it plays a functional role in many neurological disorders. Some natural compounds from Chinese herbs, which were shown to have the property as that of receptor agonist, might provide a rich source in search of new candidates for therapeutic use. For exploring this possibility, we developed a cell-based high throughput (HTS) D5 receptor assay to screen the herb-based natural compound library established in our centre. The D5 receptor plasmid (hD5R/pcDNA3.1) and reporter gene plasmid (4 x CRE/TK/Luci/pGL3) were co-transfected into HEK293 cell line. After G418 being selected, the monoclonal cell lines bearing hD5R and the reporter gene were established and used for agonist screening. To optimize the assay condition, the effects of some factors such as cell number per well, incubation time, and the doses of SKF38393 (a potent selective partial D1-like agonist) were examined by using forskolin, a positive compound for cAMP response element. The best condition for this HTS assay included: the cell number at 5 x 10(4)/mL, the dose of forskolin at 5-20 micromol/L, the dose of SKF38393 at 100 nmol/L-100 micromol/L, and the agonist incubation time at 6 -8 h. Thereafter, water extracts from more than 200 Chinese herbs in our library were screened and three of these water extracts showed positive activity, with higher or similar activity as SKF38393. In conclusion, we have established a cell-based HTS assay for D5 receptor agonist screening, and by use of this HTS assay, 3 Chinese herbs maybe contain components exhibiting D5 receptor agonist property. This work provides an alternative vision of how to use herb medicines and a way to develop potential drugs for treatment of neurological disorders.
Asunto(s)
Agonistas de Dopamina/aislamiento & purificación , Medicamentos Herbarios Chinos/farmacología , Plantas Medicinales/química , Receptores de Dopamina D5/agonistas , Línea Celular , Evaluación Preclínica de Medicamentos/métodos , Medicamentos Herbarios Chinos/aislamiento & purificación , Ensayos Analíticos de Alto Rendimiento/métodos , HumanosRESUMEN
Present Parkinson's disease treatment strategies are far from ideal for a variety of reasons; it has therefore been suggested that partial dopamine receptor agonism might be a potential therapeutic approach with potentially fewer side effects. In the present study, we describe the in vitro characterization of the nonergot ligand SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolonemonohydrochloride). SLV308 binds to dopamine D(2), D(3), and D(4) receptors and 5-HT(1) (A) receptors and is a partial agonist at dopamine D(2) and D(3) receptors and a full agonist at serotonin 5-HT(1) (A) receptors. At cloned human dopamine D(2,L) receptors, SLV308 acted as a potent but partial D(2) receptor agonist (pEC(50) = 8.0 and pA(2) = 8.4) with an efficacy of 50% on forskolin stimulated cAMP accumulation. At human recombinant dopamine D(3) receptors, SLV308 acted as a partial agonist in the induction of [(35)S]GTPgammaS binding (intrinsic activity of 67%; pEC(50) = 9.2) and antagonized the dopamine induction of [(35)S]GTPgammaS binding (pA(2) = 9.0). SLV308 acted as a full 5-HT(1) (A) receptor agonist on forskolin induced cAMP accumulation at cloned human 5-HT(1) (A) receptors but with low potency (pEC(50) = 6.3). In rat striatal slices SLV308 concentration-dependently attenuated forskolin stimulated accumulation of cAMP, as expected for a dopamine D(2) and D(3) receptor agonist. SLV308 antagonized the inhibitory effect of quinpirole on K(+)-stimulated [(3)H]-dopamine release from rat striatal slices (pA(2) = 8.5). In the same paradigm, SLV308 had antagonist properties in the presence of quinpirole (pA(2) = 8.5), but the partial D(2) agonist terguride had much stronger antagonistic properties. In conclusion, SLV308 combines high potency partial agonism at dopamine D(2) and D(3) receptors with full efficacy low potency serotonin 5-HT(1) (A) receptor agonism and is worthy of profiling in in vivo models of Parkinson's disease.
Asunto(s)
Benzoxazoles/química , Benzoxazoles/farmacología , Agonistas de Dopamina/farmacología , Enfermedad de Parkinson/tratamiento farmacológico , Piperazinas/farmacología , Receptores de Dopamina D2/agonistas , Agonistas del Receptor de Serotonina 5-HT1 , Agonistas de Receptores de Serotonina/farmacología , Animales , Benzoxazoles/aislamiento & purificación , Unión Competitiva/efectos de los fármacos , Unión Competitiva/fisiología , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Encéfalo/fisiopatología , Células CHO , Colforsina/farmacología , Cricetinae , AMP Cíclico/metabolismo , Agonistas de Dopamina/química , Agonistas de Dopamina/aislamiento & purificación , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas/fisiología , Guanosina 5'-O-(3-Tiotrifosfato)/metabolismo , Humanos , Lisurida/análogos & derivados , Lisurida/farmacología , Masculino , Estructura Molecular , Enfermedad de Parkinson/metabolismo , Enfermedad de Parkinson/fisiopatología , Piperazinas/química , Piperazinas/aislamiento & purificación , Quinpirol/farmacología , Ensayo de Unión Radioligante , Ratas , Ratas Wistar , Receptor de Serotonina 5-HT1A/genética , Receptor de Serotonina 5-HT1A/metabolismo , Receptores de Dopamina D2/genética , Receptores de Dopamina D2/metabolismo , Receptores de Dopamina D3/agonistas , Receptores de Dopamina D3/genética , Receptores de Dopamina D3/metabolismo , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/metabolismo , Agonistas de Receptores de Serotonina/química , Agonistas de Receptores de Serotonina/aislamiento & purificaciónRESUMEN
A new method of [(11)C]-methylation is described, which attains the goals of simplicity, high radiochemical yields, speed, versatility, and automation. A standard high performance liquid chromatography (HPLC) injection loop on a standard HPLC injection valve is loaded with a solution (80 microL) of precursor (0.3-1.0 mg) in dimethyl formamide (DMF) or dimethyl sulfoxide (DMSO) (+ base if required). At ambient temperature [(11)C]-iodomethane is passed through the loop for 3-4 min with >90% trapping of activity. After a further 1-5 min, the contents of the loop are quantitatively injected onto the HPLC column for purification. Radiochemical yields are equal to or superior to conventional solution methods in all cases, even though no heat is applied. [(11)C]-labeled radiotracers that have been prepared by this method for human or animal studies include Raclopride, N-methylspiperone, Ro 15-1788, FLB 457, RTI-32, Rolipram, SCH 23390, and SKF 82957. Since no vials, transfer lines, cooling, heating, or sealing valves are required, no transfer losses occur, yields are high, and cleanup is minimal, this "loop method" is ideal for most radiopharmaceuticals prepared from [(11)C]-iodomethane.